Fabry Disease – Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–Apr 20, 2018–The “Fabry Disease – Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018” drug pipelines has been added to ResearchAndMarkets.com‘s offering.

The marketed products information covers their product details, patents (US & EU), historical and forecasted sales till 2022. It further provides the marketed products’ API manufacturer details for United States, Europe, China, and India.

The report also covers the emerging Phase III pipeline assets for Infantile Spasm including their detailed product profiles. Additionally, the report also highlights the future competitive landscape for Fabry Disease therapeutics.

Scope of the Report

A comprehensive coverage of Fabry Disease marketed products including product description, regulatory milestones, clinical trials, deals and partnerships have been elaborated in this reportPatent information around Fabry Disease marketed products in United States (US) and Europe (EU) has been highlightedAPI manufacturers details for Fabry Disease marketed therapeutics in United States, Europe, China and IndiaComprehensive coverage of the emerging therapies (Phase III) for Fabry Disease including their product description, research and development activities, collaborations and licensing deals, drug mechanism and chemical informationThe report contains historical and forecasted global sales till 2022 for each marketed product and forecasted sales till 2022 for emerging Phase III products for Fabry Disease

Key Topics Covered

Report IntroductionOverviewCausesSymptomsPathophysiologyEpidemiologyDiagnosisTreatmentEmerging Treatment StrategiesComparative Analysis of Marketed and Emerging ProductsMarketed TherapiesGalafold: Amicus TherapeuticsProduct DescriptionRegulatory MilestonesResearch and DevelopmentProduct Development ActivitiesOther Clinical ActivitiesProduct DetailsEuropeGlobal SalesGlobal Active Pharmaceutical Ingredient Manufacturers for MigalastatUnited StatesChinaPatent Details(The list continues)Emerging Therapy – Phase IIIFuture Competitive Landscape

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/vfzdpx/fabry—disease?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180420005669/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Endocrine and Metabolic Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 04/20/2018 01:46 PM/DISC: 04/20/2018 01:46 PM


Copyright Business Wire 2018.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *